Honored to present at the @RetinaWCongress panel discussion on “New Pathways in Retinal Diseases”. @RWCRetina #eyes #retina #macula #ophthalmology #biotech #biotechnology #medicine #clinicalresearch #clinicaltrials #drugdevelopment #suprachoroidal #xipere https://t.co/a5X8MEIMHo Source by Thomas Ciulla, MD, MBA Return to main website.
RT @Healio_OSN: Two phase 3 studies showed that suprachoroidal triamcinolone acetonide injections led to significant improvement in visual… Source by Thomas Ciulla, MD, MBA Return to main website.
At #arvo2022, with colleagues who worked at Spark prior to #Luxturna launch, which involved novel functional vision #endpoints, complex #genetictesting paradigms, new administration procedures at treatment centers, & unique reimbursement pathways associated with #genetherapy https://t.co/MMo8oZeVD5 Source by Thomas Ciulla, MD, MBA Return to main website.
Congrats to colleagues & partners with numerous #arvo2022 presentations on #suprachoroidal delivery, with the SCS Microinjector. In addition to FDA-approved #Xipere, 6 clinical trials globally are assessing 4 different investigational therapies, using the SCS Microinjector.#eye https://t.co/TFshyatTTH
Source by Thomas Ciulla, MD, MBA
RT @eyetubenet: Join Drs. Sunil Srivastava, Dilraj Grewal, and Steven Yeh for this #CME Series: Harnessing the Suprachoroidal Space for the… Source by Thomas Ciulla, MD, MBA Return to main website.
RT @ThomasCiullaMD: Just published: https://t.co/pGZQQVEySc Disease progression pathways of wet AMD: opportunities for new target discovery… Source by Thomas Ciulla, MD, MBA Return to main website.
Looking forward to ARVO 2022 meeting next week. Check out these excellent presentations providing insights on #suprachoroidal delivery of investigational agents, a corticosteroid, and a #genetherapy.
RT @ThomasCiullaMD: This webinar on #suprachoroidal delivery features an amazingly talented team: Source by Thomas Ciulla, MD, MBA Return to main website.